Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$250.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Symbio Pharmaceuticals Ltd Amends Consolidated Full-year Outlook for FY 2013


Friday, 26 Jul 2013 02:30am EDT 

Symbio Pharmaceuticals Ltd announced that it has lowered the consolidated full-year outlook for revenue from JPY 1,927 million to JPY 1,563 million, but has raised the consolidated full-year outlook for operating profit (loss) from JPY (1,889 million) to JPY (1,743 million), ordinary profit (loss) from JPY (1,922 million) to JPY (1,749 million), net profit (loss) from JPY (1,926 million) to JPY (1,753 million) and earning (loss) per share from JPY (81.03) to JPY (76.10) for the fiscal year ending December 31, 2013. The negative revenue outlook is mainly due to the adjustment of commercial stocks of a product. The positive revenue outlook is mainly due to reduction of clinical development costs and other costs. 

Company Quote

265.0
-2.0 -0.75%
20 Aug 2014